Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea

December 21, 2010 Press Release Mitsubishi Tanabe Pharma Corporation Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea Osaka, Japan, December 21, 2010---Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya ) today announced that the Company has concluded an agreement with Dong-A Pharma ceutical Co., Ltd. (head office: Seoul, South Korea; President & CEO: Won-Bae Kim) under which Mitsubishi Tanabe shall grant an exclusive Korean rights to de velop, manufacture, and market bepotastine besilate, the active ingredient of TALION ®, for ophthalmic use. Bepotastine besilate was co-developed by Mitsushi Tanabe Pharma and Ube Industries, Ltd. (head office: Ube, Yamaguchi, Japan; President & Representative Director: Michio Takeshita) who discovered, and then it has been marketed in Japan by Mitsubishi Tanabe Pharma for treatment of allergic disorders under the brand name TALION® since 2000. In South Korea, Dong-A Pharma ceutical has marketed it as TALION® Tablets since 2004, under the licensing agreement with the Company, and now keeps the top share in Korean anti-histamine market. Dong-A Pharmaceutical plans to make its efforts to develop an eyedrop formulation of TALION®, and aims to launch it in 2012. With this new lineup, Dong-A Pharmaceutical will bolster its franchise of both TALION® and its ophthalmologic field in South Korea. Mitsubishi Tanabe Pharma, thr ough this strategic alliance, continues to maximize the product value of TALION®. Contact for further information: Corporate Communications Department Phone: +81 6-6205-5211

The release as fetched from its publisher. tanabe-pharma.com ↗